Free Trial
LON:MXC

Argent BioPharma (MXC) Share Price, News & Analysis

GBX 22
+1.00 (+4.76%)
(As of 04/3/2024)
Today's Range
22
22
50-Day Range
19.80
22
52-Week Range
13.10
600
Volume
264 shs
Average Volume
26,353 shs
Market Capitalization
£9.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MXC stock logo

About Argent BioPharma Stock (LON:MXC)

MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. In addition, the company provides Irnican that is in preclinical phase for the tetrahydrocannabinol, as well as offers ArtemiC and non-pharma products. Further, it offers consulting services, including clinical research services. MGC Pharmaceuticals Limited was founded in 2014 and is based in Subiaco, Australia.

MXC Stock Price History

MXC Stock News Headlines

Argent BioPharma Ltd (RGT)
Brace Yourself: Experts calling for Bitcoin to hit $100k
For the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.
MGC Pharmaceuticals Ltd (MXC)
MGC Pharmaceuticals Ltd MXC
MGC Pharma receives Saudi approval for ArtemiC
Brace Yourself: Experts calling for Bitcoin to hit $100k
For the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.
MGC Pharma completes share placing and consolidation
MGC Pharmaceuticals clarifies share consolidation and new fundraise
See More Headlines
Receive MXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Argent BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Petroleum And Natural Gas
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Net Income
£-17,020,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£1.32 million
Book Value
GBX 4 per share

Miscellaneous

Free Float
N/A
Market Cap
£9.65 million
Optionable
Not Optionable
Beta
1.03
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Roby Reuven Zomer (Age 44)
    Co-Founder, CEO, MD & Executive Director
    Comp: $183.3k
  • Mr. Tom Cairns
    Chief Accounting Officer
  • Ms. Yifat Steuer
    Deputy CEO & COO
  • Ms. Nicole Ann Godresse
    Global Chief Sales Officer
  • Mr. Amir Polak
    Chief Pharmaceutical Development Officer
  • Ms. Sabina Suljakovic
    Head of the Quality Assurance Department
  • Dr. Nadya Lisovoder
    Chief Medical Officer
  • Ms. Sasha Friedman
    Deputy CEO
  • Yair Tal
    Chief Information Security Officer
  • Mr. Robert Clements
    Chief Commercial Officer

MXC Stock Analysis - Frequently Asked Questions

How have MXC shares performed this year?

Argent BioPharma's stock was trading at GBX 27 at the start of the year. Since then, MXC stock has decreased by 18.5% and is now trading at GBX 22.
View the best growth stocks for 2024 here
.

How do I buy shares of Argent BioPharma?

Shares of MXC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:MXC) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners